Stempeutics Research Pvt. Ltd. (SR) is based in Bangalore and is a late stage life science company focussed on developing and commercialising novel therapeutics, based on adult stem cells. It was incorporated in January 2006 and entered into a strategic alliance with Cipla in 2009. SR’s strength lies in developing innovative stem cell products by nurturing cutting edge research and clinical applications through dedicated efforts of its highly qualified team.
Presently, it has three innovative products: Stempeucel®, StempeucareTM and StempeutronTM.
In 2016, DCGI (Indian FDA) granted limited approval of Stempeucel® product sales for the treatment of CLI patients due to Buerger’s disease. Stempeucel® is the first innovative stem cell based biological product to be approved by DCGI for limited sales. It has put SR and India on the global map for cutting edge drug discovery, being one of the few stem cell products to be approved by a regulatory body, anywhere in the world.